20 Takeover Rumors Hedge Funds Are Buying

5. Blueprint Medicines Corporation (NASDAQ:BPMC)

No. of Hedge Funds: 56

Headquartered in Massachusetts, Blueprint Medicines Corporation (NASDAQ:BPMC) is a precision therapy company focusing on genomically defined cancers and hematologic diseases. Their marketed products, AYVAKIT® and GAVRETO®, target rare mutations in PDGFRA and RET, respectively. Though facing heavy competition in the market, Blueprint Medicines Corporation (NASDAQ:BPMC) thrives by leveraging its proprietary kinase platform to design highly selective inhibitors. The company gains the position as a key player in targeted oncology by aiming to improve the quality of life in biomarker-driven subpopulations.

The company’s focus on precision cancer therapies has included it in the subject of takeover rumors. Since 2022, experts have noted larger pharmaceutical companies showing interest in purchasing the Blueprint Medicines Corporation (NASDAQ:BPMC)’s portfolio of precision cancer therapies. Accordingly, the company is willing to make a deal and use the opportunity. The options included both strategic partnerships and acquisitions. With the M&A activity in the biopharma sector expected to rise to a deal value of $70 to $90 billion, the possibility of the company’s takeover stands high as well.

Institutional interest in the company is strong, with 56 hedge funds having stakes in Blueprint Medicines Corporation (NASDAQ:BPMC) stock. It reflects high expectations from the company, including takeover rumors that give way to a rise in value.